SP-420 is under clinical development by Abfero Pharmaceuticals and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SP-420’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SP-420 overview

SP-420 is under development for the treatment of transfusion dependent beta-thalassemia, iron overload, Parkinson's Disease, age related macular degeneration, retinal degeneration, ischemia reperfusion. The drug candidate is administered orally.

It was also under development for the treatment of myelodysplastic (MDS) and myelofibrosis patients.

Abfero Pharmaceuticals overview

Abfero Pharmaceuticals is a clinical stage pharmaceutical company that specializes in healthcare and medical industry. The company is headquartered in Lexington, Massachusetts, the US

For a complete picture of SP-420’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.